Toll-like receptor 3–activated allogeneic umbilical cord blood–derived mesenchymal stromal cells as an adjunct for the treatment of synovial sepsis in 3 horses

Key Points

• This research aims to explore the effectiveness of TLR-3-activated umbilical cord blood-derived mesenchymal stromal cells (CB-MSCs) for treating synovial sepsis.
• Utilized a case series approach.
• Administered TLR-3-activated CB-MSCs as adjunctive therapy.
• Included horses with chronic or antimicrobial-resistant infections.
• Demonstrated positive outcomes in the management of synovial sepsis.
• Improved healing in horses with chronic infections.
• Highlighted potential for TLR-3 activation to enhance therapeutic effectiveness.

Abstract